Teva Pharmaceutical Industries (TEVA) is down 6.7% today. Here is some analysis on what might have caused this price movement.
Analysis: The sharp move appears tied primarily to Teva’s disclosure that its head of global R&D and chief medical officer is stepping down immediately, an unexpected leadership change that arrived just one week after the company’s R&D Day. Investors may also be weighing the company’s ongoing legal overhang after a new settlement in the multistate generic-drug price-fixing case, even though terms were not disclosed.
Details:
Sources:
SEC, Teva Pharmaceuticals, Yahoo Finance
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$TEVA Insider Trading Activity
$TEVA insiders have traded $TEVA stock on the open market 24 times in the past 6 months. Of those trades, 0 have been purchases and 24 have been sales.
Here’s a breakdown of recent trading of $TEVA stock by insiders over the last 6 months:
- ROBERTO MIGNONE sold 367,600 shares for an estimated $14,356,801
- RICHARD D FRANCIS (President and CEO) has made 0 purchases and 2 sales selling 256,153 shares for an estimated $10,770,530.
- ELIYAHU SHARON KALIF (EVP, Chief Financial Officer) sold 106,563 shares for an estimated $3,633,308
- MARK SABAG (See "Remarks") sold 44,710 shares for an estimated $1,973,544
- RICHARD DANIELL (EVP, Europe Commercial) has made 0 purchases and 2 sales selling 45,003 shares for an estimated $1,928,944.
- AMIR WEISS (Chief Accounting Officer) has made 0 purchases and 5 sales selling 26,734 shares for an estimated $1,099,350.
- DOV BERGWERK (Interim Cheif Legal Officer) has made 0 purchases and 2 sales selling 26,260 shares for an estimated $1,095,567.
- ERIC A HUGHES (See "Remarks") sold 25,578 shares for an estimated $892,050
- MATTHEW SHIELDS (EVP, Global Operations) has made 0 purchases and 2 sales selling 26,184 shares for an estimated $853,876.
- EVAN LIPPMAN (EVP, Business Development) sold 18,600 shares for an estimated $680,291
- PLACID JOVER (See "Remarks") sold 12,827 shares for an estimated $447,350
- BRIAN SAVAGE (Interim Chief Legal Officer) has made 0 purchases and 3 sales selling 7,342 shares for an estimated $285,215.
- RONIT SATCHI-FAINARO sold 415 shares for an estimated $15,458
- TAL ZVI ZAKS sold 17 shares for an estimated $592
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$TEVA Hedge Fund Activity
We have seen 297 institutional investors add shares of $TEVA stock to their portfolio, and 441 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM removed 42,027,927 shares (-97.1%) from their portfolio in Q3 2026, for an estimated $1,664,305,909
- MENORA MIVTACHIM HOLDINGS LTD. removed 39,854,383 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $1,578,233,566
- VANGUARD CAPITAL MANAGEMENT LLC added 32,513,097 shares (+1225060.2%) to their portfolio in Q3 2026, for an estimated $1,287,518,641
- HAREL INSURANCE INVESTMENTS & FINANCIAL SERVICES LTD. removed 13,483,390 shares (-28.0%) from their portfolio in Q3 2026, for an estimated $533,942,244
- VANGUARD FIDUCIARY TRUST CO added 10,457,615 shares (+inf%) to their portfolio in Q3 2026, for an estimated $414,121,554
- MEITAV INVESTMENT HOUSE LTD removed 9,947,045 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $393,902,982
- WELLINGTON MANAGEMENT GROUP LLP removed 7,671,157 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $303,777,817
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$TEVA Analyst Ratings
Wall Street analysts have issued reports on $TEVA in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 11/19/2026
- HC Wainwright & Co. issued a "Buy" rating on 11/17/2026
- Argus Research issued a "Buy" rating on 11/17/2026
- Piper Sandler issued a "Overweight" rating on 11/12/2026
- Leerink Partners issued a "Outperform" rating on 11/05/2026
- TD Cowen issued a "Buy" rating on 11/04/2026
- JP Morgan issued a "Overweight" rating on 10/12/2026
To track analyst ratings and price targets for $TEVA, check out Quiver Quantitative's $TEVA forecast page.
$TEVA Price Targets
Multiple analysts have issued price targets for $TEVA recently. We have seen 9 analysts offer price targets for $TEVA in the last 6 months, with a median target of $50.0.
Here are some recent targets:
- Glen Santangelo from Barclays set a target price of $50.0 on 11/19/2026
- Douglas Tsao from HC Wainwright & Co. set a target price of $54.0 on 11/17/2026
- An analyst from Argus Research set a target price of $50.0 on 11/17/2026
- David Amsellem from Piper Sandler set a target price of $56.0 on 11/12/2026
- Daniel Clark from Leerink Partners set a target price of $52.0 on 11/05/2026
- Joseph Thome from TD Cowen set a target price of $57.0 on 11/04/2026
- Chris Schott from JP Morgan set a target price of $50.0 on 10/12/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.